Profile data is unavailable for this security.
About the company
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company monitors investments in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by the Company such as Exelon and Impavido.
- Revenue in CAD (TTM)413.85m
- Net income in CAD-3.49m
- Incorporated2015
- Employees745.00
- LocationKnight Therapeutics Inc3400 De Maisonneuve Blvd WMONTREAL H3Z 3B8CanadaCAN
- Phone+1 (514) 484-4483
- Fax+1 (514) 481-4116
- Websitehttps://knighttx.com/
More ▼
Mergers & acquisitions
| Acquired company | GUD:TOR since announced | Transaction value |
|---|---|---|
| Paladin Pharma Inc | 7.71% | 89.13m |
Data delayed at least 15 minutes, as of Feb 10 2026 20:15 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Charlotte's Web Holdings Inc | 66.74m | -29.39m | 120.05m | 112.00 | -- | 9.65 | -- | 1.80 | -0.1852 | -0.1852 | 0.4203 | 0.0788 | 0.4893 | 1.39 | 36.51 | 595,867.80 | -21.55 | -28.40 | -24.66 | -32.20 | 44.26 | 46.82 | -44.04 | -74.38 | 1.65 | -6.81 | 0.8408 | -- | -21.36 | -12.09 | -25.42 | -- | -23.86 | -- |
| Biosyent Inc | 42.18m | 8.63m | 156.46m | 0.00 | 18.40 | 3.88 | 13.42 | 3.71 | 0.7479 | 0.7479 | 3.65 | 3.54 | 0.9045 | 1.64 | 8.01 | -- | 18.52 | 15.49 | 21.83 | 17.84 | 77.46 | 79.98 | 20.47 | 20.11 | 4.23 | -- | 0.0219 | 15.57 | 10.89 | 10.33 | 12.54 | 10.72 | -39.09 | -- |
| Auxly Cannabis Group Inc | 146.00m | 45.34m | 170.88m | 388.00 | 4.07 | 0.977 | 3.05 | 1.17 | 0.0307 | 0.0307 | 0.1019 | 0.1279 | 0.5401 | 1.75 | 6.63 | 376,275.80 | 16.77 | -18.35 | 22.80 | -23.05 | 52.00 | 26.34 | 31.05 | -72.02 | 1.05 | 3.07 | 0.2767 | -- | 21.02 | 71.06 | 63.27 | -- | -40.74 | -- |
| Aurora Cannabis Inc | 373.12m | -88.26m | 273.65m | 1.10k | -- | 0.5149 | -- | 0.7334 | -1.57 | -1.58 | 6.64 | 9.46 | 0.4545 | 1.52 | 7.96 | 338,890.10 | -11.73 | -- | -15.10 | -- | 1.35 | -- | -25.80 | -- | 1.48 | -- | 0.151 | -- | 27.32 | -- | 130.82 | -- | -- | -- |
| Cipher Pharmaceuticals Inc | 67.84m | 23.53m | 365.48m | 61.00 | 16.42 | 2.40 | 11.10 | 5.39 | 0.8886 | 0.8886 | 2.55 | 6.09 | 0.3322 | 2.15 | 4.29 | 1,112,206.00 | 11.52 | 19.63 | 13.03 | 23.17 | 74.32 | 79.74 | 34.69 | 59.54 | 0.9766 | 5.74 | 0.1052 | 0.00 | 57.66 | 8.24 | -43.36 | 34.34 | 127.59 | -- |
| Spectral Medical Inc | 2.71m | -41.69m | 376.86m | 29.00 | -- | -- | -- | 139.32 | -0.1455 | -0.1456 | 0.0095 | -0.2375 | 0.331 | 4.43 | 7.03 | 93,275.86 | -510.19 | -135.57 | -- | -711.89 | 56.16 | 55.19 | -1,541.33 | -581.02 | 0.1044 | -0.1904 | -- | -- | 43.05 | -4.43 | 0.7223 | -- | -30.03 | -- |
| Knight Therapeutics Inc | 413.85m | -3.49m | 582.09m | 745.00 | -- | 0.7735 | 11.20 | 1.41 | -0.0378 | -0.0378 | 4.12 | 7.69 | 0.4116 | 1.84 | 3.96 | 555,498.00 | -0.3474 | 0.0976 | -0.4015 | 0.1143 | 42.49 | 46.11 | -0.844 | 0.351 | 1.68 | -- | 0.1217 | 0.00 | 13.13 | 50.90 | 125.73 | -21.48 | 60.58 | -- |
| Canopy Growth Corp | 278.39m | -327.29m | 600.52m | 960.00 | -- | 0.7286 | -- | 2.16 | -1.85 | -1.84 | 1.16 | 2.06 | 0.2452 | 2.08 | 7.59 | 289,988.50 | -28.83 | -30.76 | -31.54 | -33.95 | 26.56 | 8.54 | -117.57 | -315.36 | 4.26 | -0.1761 | 0.2518 | -- | -9.47 | -7.57 | -24.90 | -- | -56.47 | -- |
| DRI Healthcare Trust | 192.69m | -52.24m | 893.87m | 36.00 | -- | 2.07 | 17.96 | 4.64 | -0.9453 | -0.9453 | 3.45 | 7.93 | 0.2149 | -- | 3.91 | 5,352,556.00 | -5.83 | -- | -6.38 | -- | -- | -- | -27.11 | -- | -- | 1.82 | 0.5077 | -- | 16.24 | -- | -103.68 | -- | -- | -- |
| Cronos Group Inc | 179.40m | 48.93m | 1.34bn | 626.00 | 29.10 | 0.9316 | 19.18 | 7.50 | 0.1227 | 0.1227 | 0.4619 | 3.83 | 0.112 | 1.57 | 5.56 | -- | 3.51 | -8.99 | 3.81 | -9.77 | 43.35 | 2.22 | 31.36 | -159.15 | 21.28 | -- | 0.00 | -- | 34.82 | 37.71 | 158.81 | -48.79 | -19.52 | -- |
Data as of Feb 10 2026. Currency figures normalised to Knight Therapeutics Inc's reporting currency: Canadian Dollar CAD
30.39%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Gestion de Portefeuille Strat�gique Medici, Inc.as of 21 Mar 2025 | 14.99m | 15.10% |
| QV Investors, Inc.as of 28 Nov 2025 | 6.20m | 6.24% |
| Dimensional Fund Advisors LPas of 08 Jan 2026 | 2.48m | 2.49% |
| Mawer Investment Management Ltd.as of 30 Jun 2025 | 2.13m | 2.15% |
| Artisan Partners LPas of 30 Sep 2025 | 1.29m | 1.30% |
| 1832 Asset Management LPas of 30 Jun 2025 | 1.06m | 1.07% |
| COTE 100, Inc.as of 30 Jun 2024 | 852.75k | 0.86% |
| WCM Investment Management LLCas of 31 Jan 2026 | 548.54k | 0.55% |
| McElvaine Investment Management Ltd.as of 30 Jun 2025 | 359.90k | 0.36% |
| CI Investments, Inc.as of 30 Jun 2025 | 259.19k | 0.26% |
More ▼
Data from 30 Jun 2024 - 02 Feb 2026Source: FactSet Research Systems Inc.
